|
|
profit of Rs 116.6 crore for the third quarter of this fiscal, which ended on Sep 30, when compared to the Rs 394.5 crore loss reported during the corresponding period last fiscal.
But the net sales of the drug manufacturer have been registered at Rs 1,720.5 crore which is about 18% less when compared to the Rs 18,88.4 crore net sales registered during the corresponding period last fiscal..
"Revenue growth in some strategic geographical markets and a sharp focus on cost efficiency has been the underlying themes this quarter. With good achievements in these fronts, we are confident that we are on the path to recovery," Ranbaxy Laboratories CEO and Managing Director Atul Sobti told.
